Julie Engers

Research Assistant Professor

Vanderbilt University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Julie Engers is a Research Assistant Professor at Vanderbilt University, USA. Her research primarily focuses on the discovery and development of allosteric modulators for various receptor targets, including muscarinic acetylcholine receptors and metabotropic glutamate receptors. Recent contributions include the identification of several promising candidates for clinical evaluation and the application of advanced synthetic methodologies in pharmacological contexts.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Nathan Schley

Associate Professor

Vanderbilt University

UNITED STATES

View details

Changho Han

Vanderbilt University

UNITED STATES

View details

Alice Rodriguez

Vanderbilt University

UNITED STATES

View details

Trever Carter

Scripps Research Institute

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Julie Engers

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Application of Deuterium in an M1 Positive Allosteric Modulator Back-Up Program: The Discovery of VU6045422

Total Synthesis and Pharmacological Evaluation of Phochrodines A–C

Discovery of Pre-Clinical Candidate VU6008055/AF98943: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust In Vivo Efficacy

Discovery of Thieno[3,2-b]pyridine-5-carboxamide and 2,3-Difluorobenzamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5

Discovery of VU0467319: an M1 Positive Allosteric Modulator Candidate That Advanced into Clinical Trials

Discovery of VU6007496: Challenges in the Development of an M1 Positive Allosteric Modulator Backup Candidate

Development of VU6036864: A Triazolopyridine-Based High-Quality Antagonist Tool Compound of the M5 Muscarinic Acetylcholine Receptor

Discovery of VU6008677: A Structurally Distinct Tricyclic M4 Positive Allosteric Modulator with Improved CYP450 Profile

Computer-Aided Design and Biological Evaluation of Diazaspirocyclic D4R Antagonists

Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM)

Development of a Selective and High Affinity Radioligand, [3H]VU6013720, for the M4Muscarinic Receptor

Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist

Discovery of structurally distinct tricyclic M4 positive allosteric modulator (PAM) chemotypes – Part 2

Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M4 positive allosteric modulator (PAM) chemotype

Discovery of structurally distinct tricyclic M4 positive allosteric modulator (PAM) chemotypes

mGlu2 and mGlu3 Negative Allosteric Modulators Divergently Enhance Thalamocortical Transmission and Exert Rapid Antidepressant-like Effects

Collaborators (4)

Nathan Schley

Changho Han

Alice Rodriguez

Trever Carter

Make your next move.